This page contains regularly updated information on Realm Therapeutics AIM securities and the Company's most significant shareholders. Realm Therapeutics is traded on AIM and no other Exchanges. There are no restrictions on the trading of Realm Therapeutics' shares

As of 13 July 2018
Number of AIM securities in issue: 116,561,917 10p Ords
There are no shares held in treasury.
Percentage of AIM Securities not in public hands: 35.62%

As of 13 July 2018, the following shareholders held interests in excess of 3% of ordinary share capital.

  Amount % Holding
OrbiMed 25,537,109 21.91%
BVF Partners LP 15,322,266 13.15%
RA Capital Management LLC 11,491,699 9.86%
Invesco Asset Management, as agent for and on behalf of its discretionary managed clients 11,162,965 9.58%
Abingworth BioEquities Master Fund Ltd. 6,384,277 5.48%
Sussex Trading Company Limited 6,048,880 5.18%
Daniel Hegglin 5,909,091 5.07%
Oracle Management Limited 5,426,780 4.66%
Kanton Services Limited 4,629,196 3.97%

Directors' Information

  Amount % Holding
Mr. Spicer 273,930 0.24%
Mr. Martin* 248,115 0.21%
Mr. Birkett 92,686 0.08%
Ms. Thorell* 50,000 0.04%
Dr. Gergel - 0.00%
Dr. Gill - 0.00%
Mr. Zweifach - 0.00%

* Executive Director

Search Investor Relations